Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 20/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.77 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29494961 | 0.83 | ADORA2B (1.00) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL1321892 | 0.83 | ADORA2B (1.00) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL10806711 | 0.82 | ADORA2B (0.98) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL14129146 | 0.80 | ADORA2B (0.94) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL17387706 | 0.80 | ADORA2B (1.00) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL16099412 | 0.79 | ADORA2B (1.00) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL25090489 | 0.78 | ADORA2B (0.73) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL2686167 | 0.77 | ADORA2B (0.68) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL1223393 | 0.76 | ADORA2B (1.00) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL31060455 | 0.76 | ADORA2B (1.00) | ADORA2BADORA2AADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024216134-A1 | COMBINATORIAL STRATEGIES TO ENHANCE VACCINIA VIRUS IN VITRO AND IN VIVO ONCOLYSIS | UNIVERSITY OF MIAMI (US) | 2024-10-17 | — | — | WO | claimed |
| US-20240219394-A1 | METHOD FOR MEASURING RESPONSE OF OLFACTORY RECEPTOR TO SUBSTANCE | AJINOMOTO CO., INC. (JP) | 2024-07-04 | — | — | US | claimed |
| EP-4382612-A1 | METHOD FOR MEASURING RESPONSE OF OLFACTORY RECEPTOR TO SUBSTANCE | AJINOMOTO CO., INC. (JP) | 2024-06-12 | — | — | EP | claimed |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | claimed |
| WO-2023039578-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION (US) | 2023-03-16 | — | — | WO | claimed |
| WO-2023013791-A1 | METHOD FOR MEASURING RESPONSE OF OLFACTORY RECEPTOR TO SUBSTANCE | 味の素株式会社 | 2023-02-09 | — | — | WO | claimed |
| US-20150297623-A1 | METHODS FOR TREATMENT OF PRIMARY CANCER AND CANCER METASTASIS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-10-22 | — | — | US | claimed |
| US-20260124299-A1 | BITE-ACTIVATED CAR-T CELLS | Vivia Biotech Sl (ES) | 2026-05-07 | — | — | US | disclosed |
| US-20260125449-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | JUNO THERAPEUTICS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260109774-A1 | CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR B-CELL MATURATION ANTIGEN AND ENCODING POLYNUCLEOTIDES | JUNO THERAPEUTICS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-12583904-B2 | Articles of manufacture and methods for treatment using adoptive cell therapy | JUNO THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260070892-A1 | FUNCTIONALIZED AMINOTRIAZINES | LEADXPRO AG (CH) | 2026-03-12 | — | — | US | disclosed |
| US-12569445-B2 | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof | HALOZYME HYPERCON, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-2118100-A1 | NEW 3- ([1,2,4] TRIAZOLO [4,3-A] PYRIDIN-7-YL)BENZAMIDE DERIVATIVES | Almirall, S.A. (ES) | 2009-11-18 | — | — | EP | disclosed |
| WO-2009132774-A1 | NEW SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P39 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL, S. A. (ES) | 2009-11-05 | — | — | WO | disclosed |
| EP-2113503-A1 | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors | Laboratorios Almirall, S.A. (ES) | 2009-11-04 | — | — | EP | disclosed |
| WO-2009124692-A1 | NEW SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS. | ALMIRALL, S.A. (ES) | 2009-10-15 | — | — | WO | disclosed |
| EP-2108641-A1 | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors | Laboratorios Almirall, S.A. (ES) | 2009-10-14 | — | — | EP | disclosed |
| WO-2008131922-A1 | NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES | ALMIRALL, S.A. (ES) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008107125-A1 | NEW 3-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-7-YL)BENZAMIDE DERIVATIVES | ALMIRALL, S.A. (ES) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569445-B2 | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof | ALB, S100P, S100A8 | ADORA2B 3145/4885ADORA2A 2833/4885KDM4E 3147/4885 |
| US-20260109774-A1 | CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR B-CELL MATURATION ANTIGEN AND ENCODING POLYNUCLEOTIDES | CD2BP2, CD22, FCGR2A | ADORA2B 2764/4885ADORA2A 2778/4885KDM4E 2334/4885 |
| US-20260070892-A1 | FUNCTIONALIZED AMINOTRIAZINES | ADORA2B, TBXA2R, CNR1 | ADORA2B 1/4885ADORA2A 7/4885KDM4E 1854/4885 |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, CD4, MCL1 | ADORA2B 2902/4885ADORA2A 1801/4885KDM4E 2914/4885 |
| US-12583904-B2 | Articles of manufacture and methods for treatment using adoptive cell therapy | CD4, CD2, ICOS | ADORA2B 3663/4885ADORA2A 1019/4885KDM4E 2844/4885 |
| US-20260125449-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | MALT1, BCL9, ICOS | ADORA2B 3782/4885ADORA2A 2189/4885KDM4E 658/4885 |
| US-20150297623-A1 | METHODS FOR TREATMENT OF PRIMARY CANCER AND CANCER METASTASIS | P2RY1, P2RX3, P2RY4 | ADORA2B 16/4885ADORA2A 8/4885KDM4E 2872/4885 |
| US-20260124299-A1 | BITE-ACTIVATED CAR-T CELLS | TNFRSF9, ICOS, CD2 | ADORA2B 1982/4885ADORA2A 2086/4885KDM4E 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.